RAMAT GAN, Israel, Feb. 11, 2019 /PRNewswire/ — OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders.
To our Shareholders,
The last year was a critical year in which we laid the foundations for the sustainable success for our Company. We defined our strategy carefully and consolidated our positioning as a company which undertakes the research and development of fully validated medical products and pharmaceuticals based on cannabis. As a company, we do not want to participate in the undifferentiated cannabis market, as we believe that this will rapidly become commoditized and any short-term value generated will disappear. Whilst the pathway we are taking is longer and more complex, it is our belief that it will deliver genuine medical benefit to patients who lack solutions to debilitating, and in